EU/3/15/1575

About

On 11 November 2015, orphan designation (EU/3/15/1575) was granted by the European Commission to Enpharma Ltd, United Kingdom, for humanised fusion protein consisting of extracellular domain of CD24 linked to IgG1 Fc domain for the prevention of graft-versus-host disease.

The sponsor's address was updated in May 2018.

The sponsor’s address was updated in October 2020.

The sponsorship was transferred to Enpharma Europe Limited, Ireland, in November 2020.

Key facts

Active substance
humanised fusion protein consisting of extracellular domain of CD24 linked to IgG1 Fc domain
Disease / condition
Prevention of graft-versus-host disease
Date of first decision
11/11/2015
Outcome
Positive
EU designation number
EU/3/15/1575

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Enpharma Europe Limited
Blackrock
2 Seapoint Avenue
Baldoyle
Dublin 13 A94 VY68
Co. Dublin
Ireland
E-mail: mail@enpharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating